Clinical Trial Update: Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma [Phase 2]

View source ↗

Summary

A Phase 2 trial of nintedanib as switch maintenance therapy for malignant pleural mesothelioma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: TERMINATED